Workflow
流感防控
icon
Search documents
中疾控:17个省份流感达到高流行水平,12月上中旬达峰可能性较大
Xin Lang Cai Jing· 2025-12-03 03:12
Core Insights - The overall trend of acute respiratory infectious diseases in China is on the rise, with influenza viruses being the primary pathogens, and a peak in influenza cases is expected around mid-December [1][4][5] Summary by Categories Current Situation - 17 provinces in China have reached a high level of influenza activity, while other provinces are at a moderate level [5] - The influenza activity level is not expected to decline to low levels for some time, indicating that influenza prevention and control measures should remain in place for the next 6-8 weeks [5] Influenza Statistics - During the 47th week of the year (November 17-23), there were 1,234 reported outbreaks of influenza-like illness across the country, with a positivity rate of 44.8% among respiratory samples from sentinel hospitals [5][6] - The positivity rate of influenza has raised public concern, with a clarification that this does not mean nearly half of the population is infected, but rather reflects the intensity of influenza activity [2][5] Regional and Temporal Trends - Except for a few provinces in East China, all other regions are experiencing moderate to high levels of influenza activity, with southern provinces reporting a positivity rate of 6.7% and northern provinces at 7.0%, both higher than the same period in previous years [6] - The current influenza season has started approximately one month earlier than in previous years [6] Demographics and Impact - The highest incidence of influenza cases is observed in the 5-14 age group, with a notable increase in outbreaks in schools and childcare facilities [7] - Vulnerable populations, including children under 5, the elderly over 60, pregnant women, and individuals with chronic diseases, are at higher risk for severe complications from influenza [4][7]
多地流感活动呈上升趋势 相关药品市场整体供应充足
Yang Shi Wang· 2025-12-03 01:54
央视网消息:当下中国多地流感多发,主要流行哪种病毒?发展趋势如何?哪些人群需要重点防护?一起来了解一下。 中国疾控中心:12月上中旬流感达峰可能性较大 中国疾控中心病毒病所国家流感中心相关负责人介绍,根据最近监测情况,流感活动水平预计在12月上中旬达峰的可能性较大。 中国疾控中心病毒病所国家流感中心主任 王大燕:所以,未来6-8周流感防控不能放松。甲型H3N2亚型流感病毒仍然占优势流 行,占比超过95%,有少量甲型H1N1亚型和乙型流感病毒同期流行。 治疗儿童流感 关键抓住"黄金48小时" 专家介绍,本次流行季,5—14岁病例明显多于其他年龄组,流感聚集性疫情数量高于上一流行季,而且几乎全部来自学校和托 幼机构。专家表示,儿童是流感的高风险人群之一,流感防治重在早识别、早治疗,感染后的 24—48小时内,病毒的复制活动达到 高峰,所以抓好治疗的"黄金48小时"非常关键。 国家卫生健康委:增加医疗服务供给 为应对流感活动的上升趋势,近日,国家卫生健康委部署各地增加医疗服务供给,通过增加门诊号源;实行分诊分流和延长服务 时段,开设延时门诊、夜间门诊、周末门诊等措施,最大限度满足群众就医需求。截止目前,全国所有二级 ...
未来6—8周流感防控不能放松 流感发展最新趋势
Yang Shi Xin Wen· 2025-12-02 13:34
Core Insights - The current flu season in China is characterized by a significant rise in acute respiratory infections, with the H3N2 subtype being the dominant strain, accounting for over 95% of cases [1][4] - Monitoring indicates that 17 provinces are experiencing high levels of flu activity, with a nationwide peak expected in mid-December [1] - The positive rate for flu-like cases in emergency departments has reached nearly 45%, but this does not imply that half of the population is infected [2] Group 1: Flu Activity and Trends - The overall trend of acute respiratory infections is increasing, with flu viruses being the primary pathogens detected [1] - The flu activity is expected to remain elevated for the next 6-8 weeks, necessitating continued prevention efforts [1] - The H3N2 subtype remains the most prevalent, with minor occurrences of H1N1 and B type flu viruses [1] Group 2: Vaccination Insights - Vaccination is emphasized as a core preventive measure against flu, and it is still beneficial to get vaccinated even after the peak season has started [3] - Individuals who have previously contracted the flu are still advised to receive the vaccine, as immunity from one strain does not protect against others [3] - It is recommended to wait until recovery from acute symptoms before getting vaccinated, especially for those with underlying health conditions [3] Group 3: Demographics and Impact - The age group of 5-14 years shows a significantly higher number of flu cases compared to other age groups, with outbreaks primarily occurring in schools and childcare facilities [4] - Factors contributing to the spread include colder temperatures leading to increased indoor activity and poor air circulation [4] - Vulnerable populations, including young children, the elderly, pregnant women, and those with chronic illnesses, are at higher risk for severe complications [4]
多地进入流感高发期,如何应对?
Xin Hua She· 2025-12-02 13:07
Core Insights - The flu season has arrived in China, with significant increases in flu cases reported, particularly among school-aged children [1][2][12] - The Chinese Center for Disease Control and Prevention (CDC) indicates that flu virus accounts for nearly 45% of respiratory samples tested, with flu activity at moderate to high levels across various provinces [1][2] Group 1: Flu Activity and Impact - Many regions are experiencing a surge in flu cases, with reports of increased patient volumes in hospitals, particularly in respiratory and fever clinics [2][10] - The CDC has noted a rise in school outbreaks, with a higher positive detection rate among children aged 5 to 14 compared to other age groups [2][12] Group 2: Medical Response and Preparedness - Medical institutions are ramping up their stock of antiviral medications, with significant sales increases reported for drugs like Oseltamivir and Baloxavir, showing year-on-year growth of 237% and 180% respectively [6][12] - Hospitals are optimizing their service structures to handle the influx of patients, including extended hours and additional weekend clinics [10][11] Group 3: Vaccination Efforts - Vaccination against the flu is emphasized as a key preventive measure, with increased uptake noted, particularly among children [12][14] - The CDC recommends annual flu vaccinations to reduce the risk of severe illness, especially for vulnerable populations such as children, the elderly, and those with chronic conditions [12][14] Group 4: Public Health Recommendations - Experts advise maintaining good personal hygiene practices, such as frequent handwashing and wearing masks, to mitigate the spread of the virus [15] - It is recommended that high-risk groups seek early antiviral treatment upon flu diagnosis to prevent severe outcomes [15]
防治流感,上市药企有什么“手段”?
Core Insights - The flu positive rate in China has reached nearly 45%, indicating a significant rise in flu cases, with some provinces experiencing high epidemic levels [1] - Investors are closely monitoring the supply and sales of flu medications and vaccines from listed pharmaceutical companies, which are actively preparing to meet public health needs [1] Group 1: Drug and Vaccine Supply - Multiple listed companies have reported sufficient reserves of flu medications and vaccines, ensuring stable supply capabilities [2] - Renhe Pharmaceutical has initiated a priority supply mechanism for Oseltamivir, while Dajia Weikang has adjusted production capacity based on market demand [2] - The entire supply chain, including raw material suppliers like Rhine Bio, is collaborating to ensure a robust response to market needs [2] Group 2: Vaccine Development - Companies are focusing on flu vaccines as a key area for development, with several achieving significant progress by 2025 [3] - Zhejiang Tianyuan Biopharmaceutical's quadrivalent flu vaccine "Yufening" has been approved for sale, alongside its trivalent vaccine "Yuganning" [3] - Baike Bio has innovated with a freeze-dried nasal spray flu vaccine, which has been upgraded to a liquid form for easier administration [3] Group 3: Treatment Options - Companies are building a diverse matrix of flu medications to address various symptoms and treatment needs [5] - Zhongsheng Pharmaceutical is advancing the commercialization of Anladiwei tablets for treating uncomplicated influenza, while Jichuan Pharmaceutical is developing a novel flu treatment [5] - Oseltamivir remains a commonly used antiviral, with multiple companies like Renfu Pharmaceutical and Dajia Weikang actively involved in its production [5][6] Group 4: Symptomatic Relief - Several companies are providing symptomatic treatments for flu, including Lisheng Pharmaceutical's Acetaminophen and various products from Zhenbaodao for symptom relief [6] - Companies like Foci Pharmaceutical produce a range of cold and flu medications, ensuring comprehensive treatment options for patients [6]
日本疫情大暴发!
Core Insights - Japan is experiencing a significant flu outbreak, with over 190,000 reported cases in the week ending November 23, marking a 1.4 times increase from the previous week [1] - The flu epidemic has reached "alert" levels in 39 out of 47 prefectures, with the situation in Fukushima being particularly severe, reporting the highest infection levels in nearly a decade [2][4] Summary by Sections Flu Cases and Trends - As of November 23, Japan reported 196,900 flu cases, averaging 51.12 cases per reporting medical institution, with a continuous increase for 14 weeks [1] - The flu outbreak is approaching last year's peak levels, which saw an average of 64.39 cases per institution [1] Regional Impact - 39 prefectures have reached flu epidemic alert levels, an increase of 15 from the previous week, with Miyagi, Fukushima, and Iwate being the most affected [3] - In Fukushima, 4,162 cases were reported from 48 medical institutions, a rise of over 1,300 cases from the previous week, marking the highest level since 2015 [4] Educational Impact - Due to the flu spread, 8,817 schools have closed or partially closed classes across Japan [3] Healthcare System Strain - Medical institutions are under significant pressure due to the rapid increase in flu cases, with shortages of common cold medications and antibiotics reported [6] - The upcoming year-end period will further complicate access to medical care as many institutions will reduce services [7] Early Flu Season Factors - Japan entered the flu season earlier than last year, attributed to decreased public health measures and increased international travel [9][10] - Factors such as climate change and lower vitamin D synthesis due to less sun exposure may have contributed to a decline in immunity among the population [10]
全国进入流感快速上升阶段
第一财经· 2025-11-26 11:08
Core Insights - The flu is currently on the rise in China, with most provinces reaching epidemic levels, as reported by the Chinese Center for Disease Control and Prevention [1] - The latest report indicates that flu-like cases in sentinel hospitals have reached the highest levels in four years, with northern provinces reporting 7.0% and southern provinces 6.7% of emergency cases being flu-like [1] - A total of 955 flu-like outbreaks were reported nationwide, with 741 caused by the H3N2 strain [1] - The World Health Organization estimates that seasonal flu can lead to 3 to 5 million severe cases and 290,000 to 650,000 respiratory disease-related deaths globally each year [1] - The flu vaccine is the most effective and economical method to prevent flu, significantly reducing severe cases and mortality rates [1] Vaccination Insights - Annual flu vaccination is recommended as the vaccine is updated each year based on global monitoring data to match circulating strains [1] - The Chinese Center for Disease Control and Prevention released the "Technical Guidelines for Influenza Vaccine Prevention (2025-2026)" on November 3, indicating changes in the vaccine components for the H3N2 strain compared to the previous year [1]
儿童“中招”流感怎么办?专家:抓住48小时黄金干预期
Ren Min Wang· 2025-11-25 09:10
王亚军表示,感染流感后,会出现反复持续高热,并伴有明显乏力、全身肌肉关节疼痛等症状。有 些儿童会以咽痛、头疼或肌肉酸痛等为首发症状,如果出现这一情况,提示家长们要特别警惕和注意。 万一儿童感染流感怎么办?王亚军建议,要早干预、防加重。48小时之内是黄金干预期,因为此时 病毒在体内复制的量还不多,确诊之后应该尽早给予抗病毒治疗。有一些中成药,比如小儿肺热咳喘口 服液,在医生指导下,联合西药规范使用,可以快速缓解患儿咳嗽、发热等症状,并缩短症状持续的时 间。 在日常生活中,家长该如何为孩子筑起防线?中疾控建议,采取"疫苗+卫生习惯"的双防线策略。 根据日前发布的《中国流感疫苗预防接种技术指南(2025—2026)》建议,所有≥6月龄且无接种禁忌 的人都应接种流感疫苗。 时值初冬,天气转寒。依托中国流感监测系统,疾控部门对各地流感活动实时开展监测预警和风险 评估,当前我国总体流感活动属于上升阶段,甲型H3N2亚型占比超过95%,有少量甲型H1N1和乙型流 感病毒同期流行。 针对儿童这一重点人群,流感防控的关键是什么?需要注意哪些问题?首都医科大学附属首都儿童 医学中心呼吸内科副主任医师王亚军进行了讲解。 "不同于普 ...
南新制药:以全维产品矩阵发力流感防控
Zhong Zheng Wang· 2025-11-24 06:03
Core Viewpoint - The company, Nanxin Pharmaceutical, is leveraging its technological advantages in the field of cold and antiviral drugs to ensure the production and supply of related treatment medications amid rising influenza virus activity levels in China [1][2]. Group 1: Product Portfolio and Innovation - Nanxin Pharmaceutical has established a comprehensive product matrix for influenza prevention and treatment, covering injectable and oral forms, as well as therapies for viral and bacterial infections, and antipyretic analgesics [1]. - The company's Palivizumab Sodium Injection is a representative of neuraminidase inhibitors, recognized as a core choice for influenza treatment in the latest national guidelines [1]. - The company is currently in the III phase of clinical trials for an inhalation solution of Palivizumab, which utilizes nebulization for direct action on the respiratory tract, enhancing patient compliance and offering a new option for influenza treatment [2]. Group 2: Targeted Treatments for Specific Populations - The company has developed a formulation of Oseltamivir Phosphate suitable for young children and elderly patients, addressing the need for appropriate dosage forms in these demographics [1]. - Nanxin Pharmaceutical offers a range of supportive treatments for influenza symptoms, including exclusive products like Compound Ibuprofen Tablets and formulations specifically designed for children, which have become common choices in pediatric care [2]. Group 3: Future Outlook and Commitment - The company aims to continuously optimize its product structure and provide efficient solutions for the prevention and treatment of influenza and other respiratory diseases, demonstrating its commitment to public health [2].
中疾控:预计未来流感活动还将进一步上升
Ren Min Wang· 2025-11-21 09:31
Core Viewpoint - The current flu season in China is experiencing a significant rise in activity, with the predominant strain being H3N2, and there is a notable increase in flu outbreaks in schools and childcare institutions [1][2]. Group 1: Flu Virus Evolution and Current Situation - The flu virus undergoes antigenic drift, leading to seasonal outbreaks, but there is no evidence of increasingly stronger mutations or new infectious diseases [1][2]. - The current flu season (2025-2026) is characterized by the co-circulation of H3N2, H1N1, and B-type flu viruses, with a notable increase in flu activity across many provinces [2]. Group 2: Public Health Recommendations - A dual prevention strategy of "vaccination + hygiene habits" is recommended to reduce infection and severe illness risks [3]. - Key hygiene practices include frequent handwashing, using disinfectant wipes on commonly touched surfaces, wearing masks, and maintaining good respiratory hygiene [3]. - Monitoring health in key institutions like schools and nursing homes is crucial, along with ensuring proper ventilation and cleanliness [3].